These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8109301)

  • 21. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
    Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
    Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
    J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
    Vaamonde J; Flores JM; Weisser R; Ibañez R; Obeso JA
    Mov Disord; 2009 Apr; 24(5):762-5. PubMed ID: 19224589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
    Boyce S; Rupniak NM; Steventon MJ; Iversen SD
    Neurology; 1990 Jun; 40(6):927-33. PubMed ID: 2140595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
    Carbone F; Djamshidian A; Seppi K; Poewe W
    CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Clarke CE; Boyce S; Robertson RG; Sambrook MA; Crossman AR
    J Neurol Sci; 1989 May; 90(3):307-14. PubMed ID: 2786926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
    Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F
    Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
    Lincoln L; Fisher R; Jackson MJ; Jenner P; Neumeyer J; Sromek AW; Lees AJ; Rose S
    Mov Disord; 2016 Sep; 31(9):1381-8. PubMed ID: 27133947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.
    Tyne HL; Parsons J; Sinnott A; Fox SH; Fletcher NA; Steiger MJ
    J Neurol; 2004 Nov; 251(11):1370-4. PubMed ID: 15592733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.